Skip to main content
. 2020 Dec 14;17(12):e1003397. doi: 10.1371/journal.pmed.1003397

Fig 4. Level of NNRTI PDR in 2035, by rate of switching to DTG-based ART and percent women eligible for DTG-based ART.

Fig 4

Panel A relates to patients on first-line ART with suppressed HIV-1 replication, and panel B to individuals failing NNRTI-based ART. The average time to switching (i.e., the inverse of the switching rate) varies from 0.5 to 10 years for individuals with viral suppression (panel A) or failure (panel B). ART, antiretroviral therapy; DTG, dolutegravir; NNRTI, non-nucleoside reverse transcriptase inhibitor; PDR, pretreatment drug resistance.